[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-retatrutide-liver-damage-myths-es":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":7,"cat":9,"icon":10,"accent":11,"date":12,"dateLabel":13,"read":14,"author":15,"image":16,"body":17,"_type":2419,"_id":2420,"_source":2421,"_file":2422,"_stem":2423,"_extension":2424},"\u002Fblog\u002Fes\u002Fretatrutide-liver-damage-myths","es",false,"","Daño hepático por retatrutida: la verificación","Verificación","tabler:microscope","#F2A93B","2026-06-27","Junio de 2026","20 min","myPeptides Team","\u002Fassets\u002Freta_hero.png",{"type":18,"children":19,"toc":2397},"root",[20,124,131,143,317,322,328,334,339,348,398,417,423,461,479,485,490,498,534,560,566,571,579,599,664,670,675,683,730,736,741,783,789,794,799,803,809,814,820,840,868,874,895,930,936,970,1010,1016,1069,1089,1125,1143,1236,1253,1345,1350,1356,1375,1421,1427,1439,1466,1472,1504,1510,1524,1530,1553,1579,1585],{"type":21,"tag":22,"props":23,"children":24},"element","disclaimer",{},[25,38,70,80,99,116],{"type":21,"tag":26,"props":27,"children":28},"p",{},[29,36],{"type":21,"tag":30,"props":31,"children":32},"em",{},[33],{"type":34,"value":35},"text","Esto es opinión y comentario científico —no consejo médico, ni una afirmación de hecho sobre ninguna persona más allá de lo que está documentado con fuentes.",{"type":34,"value":37}," Este artículo aborda, como cuestión de interés público y comentario legítimo, afirmaciones médicas que una figura pública decidió publicar ante una gran audiencia.",{"type":21,"tag":26,"props":39,"children":40},{},[41,47,49,54,56,61,63,68],{"type":21,"tag":42,"props":43,"children":44},"strong",{},[45],{"type":34,"value":46},"Hechos frente a opinión.",{"type":34,"value":48}," Cuando afirmamos hechos verificables —el estado de una licencia profesional, la titularidad de un negocio, el texto de registros y vídeos de acceso público— enlazamos las fuentes primarias para que puedas comprobarlo tú mismo. Todo lo que describimos como una ",{"type":21,"tag":30,"props":50,"children":51},{},[52],{"type":34,"value":53},"valoración",{"type":34,"value":55},", una ",{"type":21,"tag":30,"props":57,"children":58},{},[59],{"type":34,"value":60},"lectura de los datos",{"type":34,"value":62}," o nuestra ",{"type":21,"tag":30,"props":64,"children":65},{},[66],{"type":34,"value":67},"opinión",{"type":34,"value":69}," es opinión y comentario legítimo sobre declaraciones hechas en público. No pretendemos conocer la intención privada de nadie; cuando describimos un motivo o un efecto, lo describimos tal como lo vemos, no como hecho probado.",{"type":21,"tag":26,"props":71,"children":72},{},[73,78],{"type":21,"tag":42,"props":74,"children":75},{},[76],{"type":34,"value":77},"Las fuentes pueden estar incompletas.",{"type":34,"value":79}," Toda la información aquí procede de fuentes de acceso público y se presenta de buena fe y a nuestro leal saber y entender en el momento de redactarla. Los registros públicos y los informes de terceros pueden estar incompletos, cambiar o quedar superados; puede que se nos haya escapado contexto y que nos equivoquemos en algún detalle.",{"type":21,"tag":26,"props":81,"children":82},{},[83,88,90,97],{"type":21,"tag":42,"props":84,"children":85},{},[86],{"type":34,"value":87},"Derecho de réplica y corrección.",{"type":34,"value":89}," Si se te menciona aquí y crees que alguna afirmación de hecho es inexacta o está desfasada —o quieres añadir tu perspectiva— contáctanos a través de nuestro ",{"type":21,"tag":91,"props":92,"children":94},"a",{"href":93},"\u002Flegal-notice",[95],{"type":34,"value":96},"aviso legal",{"type":34,"value":98}," y lo revisaremos y, cuando proceda, lo corregiremos o actualizaremos. Agradecemos las correcciones documentadas.",{"type":21,"tag":26,"props":100,"children":101},{},[102,107,109,114],{"type":21,"tag":42,"props":103,"children":104},{},[105],{"type":34,"value":106},"No es consejo médico —ni una recomendación para usar nada.",{"type":34,"value":108}," Nada de lo que aquí se dice te indica qué hacer con tu propio cuerpo, y nada de lo aquí escrito respalda ni te da instrucciones para conseguir, dosificar o usar retatrutida ni ninguna otra sustancia —varias de ellas experimentales y no aprobadas para uso humano en muchos lugares. Las cifras de los ensayos que citamos describen resultados publicados en estudios; no son promesas de ningún resultado ni una guía de dosificación. Si estás considerando o usando alguna de estas sustancias, ",{"type":21,"tag":42,"props":110,"children":111},{},[112],{"type":34,"value":113},"acude al médico del que menos desconfíes —en persona—",{"type":34,"value":115}," antes de actuar en función de lo que leas en internet, aquí o en cualquier otro sitio.",{"type":21,"tag":26,"props":117,"children":118},{},[119],{"type":21,"tag":30,"props":120,"children":121},{},[122],{"type":34,"value":123},"Última actualización: 27 de junio de 2026. Este artículo es opinión y comentario, y puede revisarse a medida que se disponga de nueva información.",{"type":21,"tag":125,"props":126,"children":128},"h2",{"id":127},"tldr",[129],{"type":34,"value":130},"TL;DR",{"type":21,"tag":26,"props":132,"children":133},{},[134,136,141],{"type":34,"value":135},"Un vídeo de 45 minutos titulado ",{"type":21,"tag":30,"props":137,"children":138},{},[139],{"type":34,"value":140},"\"Megadosis vs. microdosis de retatrutida: ¿cuál daña más tu hígado?\"",{"type":34,"value":142}," sostiene que la retatrutida lesiona en silencio tu hígado y tu páncreas a menos que sigas un protocolo de dosificación concreto —que el presentador vende justo después, junto con los propios péptidos. Lo hemos comprobado. La versión corta:",{"type":21,"tag":144,"props":145,"children":146},"ul",{},[147,184,234,258,298],{"type":21,"tag":148,"props":149,"children":150},"li",{},[151,156,158,163,165,173,175,182],{"type":21,"tag":42,"props":152,"children":153},{},[154],{"type":34,"value":155},"El mensajero.",{"type":34,"value":157}," El \"Dr.\" Trevor Bachmeyer no es médico. Es un antiguo quiropráctico cuya licencia de California (DC 29377) fue ",{"type":21,"tag":42,"props":159,"children":160},{},[161],{"type":34,"value":162},"revocada con efecto del 8 de julio de 2020",{"type":34,"value":164},", según consta en la ",{"type":21,"tag":91,"props":166,"children":170},{"href":167,"rel":168},"https:\u002F\u002Fwww.chiro.ca.gov\u002Fabout_us\u002Fmeetings\u002F20201029_materials.pdf",[169],"nofollow",[171],{"type":34,"value":172},"Junta de Examinadores de Quiropráctica de California",{"type":34,"value":174},". Ese mismo vídeo canaliza a los espectadores hacia su coaching de pago y hacia su propia tienda de péptidos de investigación, ",{"type":21,"tag":91,"props":176,"children":179},{"href":177,"rel":178},"https:\u002F\u002Felitebiogenix.com\u002F",[169],[180],{"type":34,"value":181},"EliteBiogenix",{"type":34,"value":183},".",{"type":21,"tag":148,"props":185,"children":186},{},[187,192,194,199,201,206,208,215,217,224,225,232],{"type":21,"tag":42,"props":188,"children":189},{},[190],{"type":34,"value":191},"\"El glucagón inunda tu cuerpo de grasa.\"",{"type":34,"value":193}," Engañoso. En humanos, el glucagón fisiológico ",{"type":21,"tag":42,"props":195,"children":196},{},[197],{"type":34,"value":198},"no",{"type":34,"value":200}," descompone directamente la grasa corporal (tejido adiposo blanco): impulsa la oxidación de grasa ",{"type":21,"tag":30,"props":202,"children":203},{},[204],{"type":34,"value":205},"dentro del hígado",{"type":34,"value":207}," (",{"type":21,"tag":91,"props":209,"children":212},{"href":210,"rel":211},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32132708\u002F",[169],[213],{"type":34,"value":214},"Perry et al., Nature 2020",{"type":34,"value":216},"; ",{"type":21,"tag":91,"props":218,"children":221},{"href":219,"rel":220},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC9576180\u002F",[169],[222],{"type":34,"value":223},"Vasileva et al., 2022",{"type":34,"value":216},{"type":21,"tag":91,"props":226,"children":229},{"href":227,"rel":228},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F11344211\u002F",[169],[230],{"type":34,"value":231},"Gravholt et al., 2001",{"type":34,"value":233},").",{"type":21,"tag":148,"props":235,"children":236},{},[237,242,244,249,250,257],{"type":21,"tag":42,"props":238,"children":239},{},[240],{"type":34,"value":241},"\"Que suba la lipasa significa que tu páncreas está fallando.\"",{"type":34,"value":243}," Falso en su mayor parte. Las subidas leves y asintomáticas de enzimas son comunes y benignas; grandes conjuntos de datos de ensayos no muestran ",{"type":21,"tag":42,"props":245,"children":246},{},[247],{"type":34,"value":248},"ningún aumento de pancreatitis aguda",{"type":34,"value":207},{"type":21,"tag":91,"props":251,"children":254},{"href":252,"rel":253},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F28476871\u002F",[169],[255],{"type":34,"value":256},"Steinberg et al., Diabetes Care 2017",{"type":34,"value":233},{"type":21,"tag":148,"props":259,"children":260},{},[261,266,268,273,275,280,282,289,291,296],{"type":21,"tag":42,"props":262,"children":263},{},[264],{"type":34,"value":265},"\"La retatrutida sobrecarga y daña el hígado.\"",{"type":34,"value":267}," Lo contrario de lo que dicen los datos. En el ensayo de fase 2 sobre grasa hepática ",{"type":21,"tag":42,"props":269,"children":270},{},[271],{"type":34,"value":272},"redujo la grasa del hígado hasta un 86%",{"type":34,"value":274},", y ",{"type":21,"tag":42,"props":276,"children":277},{},[278],{"type":34,"value":279},"alrededor del 93% de los pacientes con la dosis máxima normalizaron",{"type":34,"value":281}," su grasa hepática (",{"type":21,"tag":91,"props":283,"children":286},{"href":284,"rel":285},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11271400\u002F",[169],[287],{"type":34,"value":288},"Sanyal et al., Nature Medicine 2024",{"type":34,"value":290},"). La retatrutida se está desarrollando ",{"type":21,"tag":30,"props":292,"children":293},{},[294],{"type":34,"value":295},"como tratamiento",{"type":34,"value":297}," para la enfermedad del hígado graso.",{"type":21,"tag":148,"props":299,"children":300},{},[301,306,308,315],{"type":21,"tag":42,"props":302,"children":303},{},[304],{"type":34,"value":305},"En qué acierta.",{"type":34,"value":307}," Dos cosas: no suspender el tratamiento por pánico ante un valor de lipasa aislado, y que la pérdida rápida de peso sí cuesta músculo (",{"type":21,"tag":91,"props":309,"children":312},{"href":310,"rel":311},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC12471476\u002F",[169],[313],{"type":34,"value":314},"Koceva et al., 2025",{"type":34,"value":316},"). Puntos válidos envueltos en un susto infundado.",{"type":21,"tag":26,"props":318,"children":319},{},[320],{"type":34,"value":321},"El panorama completo, y la ciencia detrás de cada línea de arriba, viene a continuación. El análisis en profundidad del final es una guía con referencias sobre toda la clase de fármacos —escrita para que puedas comprobarlo, no solo fiarte de nosotros.",{"type":21,"tag":323,"props":324,"children":327},"youtube",{"id":325,"title":326},"gb-XEtsMr-w","The video this article examines — Bachmeyer on retatrutide dosing",[],{"type":21,"tag":125,"props":329,"children":331},{"id":330},"quién-hace-la-afirmación",[332],{"type":34,"value":333},"Quién hace la afirmación",{"type":21,"tag":26,"props":335,"children":336},{},[337],{"type":34,"value":338},"Antes de la ciencia, la fuente. Se presenta como \"Dr. Trevor Bachmeyer, The Spartan\" y \"la mayor autoridad en salud del mundo\" ante una audiencia de cientos de miles. Importan dos hechos verificables.",{"type":21,"tag":26,"props":340,"children":341},{},[342],{"type":21,"tag":343,"props":344,"children":347},"img",{"alt":345,"src":346},"Cómo un susto de salud puede canalizarse hacia la venta de un producto","\u002Fassets\u002Freta_funnel.png",[],{"type":21,"tag":26,"props":349,"children":350},{},[351,353,358,360,365,367,371,373,379,380,387,389,396],{"type":34,"value":352},"Primero, ",{"type":21,"tag":42,"props":354,"children":355},{},[356],{"type":34,"value":357},"no es médico.",{"type":34,"value":359}," Es un antiguo ",{"type":21,"tag":42,"props":361,"children":362},{},[363],{"type":34,"value":364},"quiropráctico",{"type":34,"value":366},", y hasta esa licencia ha desaparecido: la licencia de California DC 29377 fue ",{"type":21,"tag":42,"props":368,"children":369},{},[370],{"type":34,"value":162},{"type":34,"value":372}," por la Junta de Examinadores de Quiropráctica de California. La medida consta en los propios documentos de la Junta (",{"type":21,"tag":91,"props":374,"children":376},{"href":167,"rel":375},[169],[377],{"type":34,"value":378},"materiales de la reunión, 29 oct 2020",{"type":34,"value":216},{"type":21,"tag":91,"props":381,"children":384},{"href":382,"rel":383},"https:\u002F\u002Fwww.chiro.ca.gov\u002Fenforcement\u002Factions.shtml",[169],[385],{"type":34,"value":386},"Acciones disciplinarias definitivas",{"type":34,"value":388},") y es verificable a través de la ",{"type":21,"tag":91,"props":390,"children":393},{"href":391,"rel":392},"https:\u002F\u002Fsearch.dca.ca.gov\u002F",[169],[394],{"type":34,"value":395},"búsqueda de licencias",{"type":34,"value":397}," del estado —los lectores pueden consultar los registros enlazados para conocer las conclusiones exactas. Sigue presentándose como \"Dr.\", un uso que, a nuestro juicio, invita a los lectores a suponer una cualificación médica vigente que no posee.",{"type":21,"tag":26,"props":399,"children":400},{},[401,403,408,410,415],{"type":34,"value":402},"Segundo, ",{"type":21,"tag":42,"props":404,"children":405},{},[406],{"type":34,"value":407},"vende aquello sobre lo que aconseja.",{"type":34,"value":409}," El vídeo dirige a los espectadores hacia una membresía de coaching de pago llamada \"Black Card\" y hacia ",{"type":21,"tag":91,"props":411,"children":413},{"href":177,"rel":412},[169],[414],{"type":34,"value":181},{"type":34,"value":416},", su tienda, que vende péptidos de investigación y SARM \"solo para investigación in vitro\". Así que la persona que te advierte de que la retatrutida te va a lesionar salvo que la dosifiques bien también te vende la guía de dosificación y los péptidos. Eso no lo descalifica por sí solo —pero es exactamente el conflicto de interés que un espectador atento debería tener presente, y es la razón de ser de este artículo.",{"type":21,"tag":125,"props":418,"children":420},{"id":419},"qué-defiende-en-realidad-siendo-justos",[421],{"type":34,"value":422},"Qué defiende en realidad —siendo justos",{"type":21,"tag":26,"props":424,"children":425},{},[426,428,433,435,440,442,447,449,454,456],{"type":34,"value":427},"Sería fácil levantar un hombre de paja, así que seamos exactos. La propia descripción de su vídeo afirma que ",{"type":21,"tag":30,"props":429,"children":430},{},[431],{"type":34,"value":432},"\"la retatrutida en sí no causa directamente daño hepático ni pancreático; el daño biológico lo causan una dosificación irresponsable y un mal seguimiento.\"",{"type":34,"value":434}," Su lista de capítulos reza ",{"type":21,"tag":30,"props":436,"children":437},{},[438],{"type":34,"value":439},"\"Inundación de grasa por glucagón → Sobrecarga del páncreas → Cascada de hígado graso → Espiral de resistencia a la insulina,\"",{"type":34,"value":441}," y luego gira hacia un ",{"type":21,"tag":30,"props":443,"children":444},{},[445],{"type":34,"value":446},"\"Protocolo de control de daños,\"",{"type":34,"value":448}," unas ",{"type":21,"tag":30,"props":450,"children":451},{},[452],{"type":34,"value":453},"\"Reglas de dosificación segura\"",{"type":34,"value":455}," y un ",{"type":21,"tag":30,"props":457,"children":458},{},[459],{"type":34,"value":460},"\"Úsalo con responsabilidad.\"",{"type":21,"tag":26,"props":462,"children":463},{},[464,466,470,472,477],{"type":34,"value":465},"Así que su tesis ",{"type":21,"tag":42,"props":467,"children":468},{},[469],{"type":34,"value":198},{"type":34,"value":471}," es \"este fármaco es veneno, evítalo.\" Es \"este fármaco te dañará ",{"type":21,"tag":30,"props":473,"children":474},{},[475],{"type":34,"value":476},"a menos que lo dosifiques a mi manera",{"type":34,"value":478},".\" Eso es más sutil, suena más creíble y es mucho más vendible —y es lo que vamos a comprobar. El problema no es que se invente estudios falsos. Es que construye un mecanismo aterrador con terminología real, y los datos de los ensayos no respaldan la parte alarmista.",{"type":21,"tag":125,"props":480,"children":482},{"id":481},"afirmación-1-la-inundación-de-grasa-por-glucagón",[483],{"type":34,"value":484},"Afirmación 1: la \"inundación de grasa por glucagón\"",{"type":21,"tag":26,"props":486,"children":487},{},[488],{"type":34,"value":489},"El motor de su argumento es el componente de glucagón de la retatrutida: supuestamente desata una inundación de grasa —ácidos grasos libres brotando de tu grasa corporal y desbordando el hígado y el páncreas.",{"type":21,"tag":26,"props":491,"children":492},{},[493],{"type":21,"tag":343,"props":494,"children":497},{"alt":495,"src":496},"El glucagón impulsa la oxidación de grasa en el hígado, no en la grasa corporal","\u002Fassets\u002Freta_glucagon.png",[],{"type":21,"tag":26,"props":499,"children":500},{},[501,503,508,510,516,518,524,525,532],{"type":34,"value":502},"Este es el mito más viejo de la fisiología del glucagón. Sí, el glucagón es una potente señal quemagrasa —",{"type":21,"tag":42,"props":504,"children":505},{},[506],{"type":34,"value":507},"pero en el hígado, no en tu grasa corporal.",{"type":34,"value":509}," El receptor de glucagón se expresa de forma densa en las células hepáticas y apenas aparece en las células grasas humanas. Cuando los investigadores eliminaron el receptor de glucagón específicamente del tejido graso en ratones, nada cambió en su metabolismo de la grasa, su peso corporal ni sus ácidos grasos libres circulantes (",{"type":21,"tag":91,"props":511,"children":513},{"href":219,"rel":512},[169],[514],{"type":34,"value":515},"Vasileva et al., AJP-Endocrinology 2022",{"type":34,"value":517},"). En humanos, elevar el glucagón a niveles fisiológicos no aumenta en absoluto la lipólisis de la grasa abdominal (",{"type":21,"tag":91,"props":519,"children":521},{"href":227,"rel":520},[169],[522],{"type":34,"value":523},"Gravholt et al., JCEM 2001",{"type":34,"value":216},{"type":21,"tag":91,"props":526,"children":529},{"href":527,"rel":528},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F1991802\u002F",[169],[530],{"type":34,"value":531},"Jensen et al., JCEM 1991",{"type":34,"value":533},"). El efecto lipolítico solo aparece en un tubo de ensayo, a concentraciones suprafisiológicas que el torrente sanguíneo nunca alcanza.",{"type":21,"tag":26,"props":535,"children":536},{},[537,539,543,545,550,551,558],{"type":34,"value":538},"Lo que el glucagón hace de verdad es impulsar la oxidación de grasa ",{"type":21,"tag":42,"props":540,"children":541},{},[542],{"type":34,"value":205},{"type":34,"value":544}," —a través de una vía de cAMP\u002FPKA y de calcio que activa la descomposición de grasa hepática (",{"type":21,"tag":91,"props":546,"children":548},{"href":210,"rel":547},[169],[549],{"type":34,"value":214},{"type":34,"value":216},{"type":21,"tag":91,"props":552,"children":555},{"href":553,"rel":554},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F38300523\u002F",[169],[556],{"type":34,"value":557},"Kajani et al., Physiological Reviews 2024",{"type":34,"value":559},")— y aumentar el gasto energético de todo el cuerpo. La imagen del glucagón \"derritiendo\" tu grasa abdominal e inundando tus órganos con ella es un artefacto in vitro, no fisiología humana. Los cimientos de su \"inundación\" se resquebrajan ya en el primer capítulo.",{"type":21,"tag":125,"props":561,"children":563},{"id":562},"afirmación-2-la-sobrecarga-del-páncreas",[564],{"type":34,"value":565},"Afirmación 2: la \"sobrecarga\" del páncreas",{"type":21,"tag":26,"props":567,"children":568},{},[569],{"type":34,"value":570},"Ahora, la lipasa elevada como prueba de que tu páncreas se encamina hacia el fallo.",{"type":21,"tag":26,"props":572,"children":573},{},[574],{"type":21,"tag":343,"props":575,"children":578},{"alt":576,"src":577},"Una subida leve de lipasa refleja una fuga inofensiva de enzima, no la destrucción del páncreas","\u002Fassets\u002Freta_pancreas.png",[],{"type":21,"tag":26,"props":580,"children":581},{},[582,584,589,591,598],{"type":34,"value":583},"La realidad, mucho menos dramática: las subidas leves y asintomáticas de lipasa y amilasa son ",{"type":21,"tag":42,"props":585,"children":586},{},[587],{"type":34,"value":588},"comunes y, por lo general, inofensivas",{"type":34,"value":590}," con esta clase de fármacos. Reflejan células acinares estimuladas pero intactas que dejan escapar un poco de enzima a la sangre —una \"fuga\" fisiológica, no el órgano digiriéndose a sí mismo. Incluso conocemos el mecanismo del receptor: los receptores de GLP-1 se asientan en las células acinares del páncreas y las animan a liberar enzima, en tejido sano y sin daño alguno (",{"type":21,"tag":91,"props":592,"children":595},{"href":593,"rel":594},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC4698438\u002F",[169],[596],{"type":34,"value":597},"Hou… Williams et al., AJP-GI 2016",{"type":34,"value":233},{"type":21,"tag":26,"props":600,"children":601},{},[602,604,609,610,615,617,624,626,631,633,640,642,647,649,653,655,662],{"type":34,"value":603},"Y los criterios de valoración duros son tranquilizadores. En los grandes programas de ensayos con liraglutida, la amilasa y la lipasa subieron de forma modesta ",{"type":21,"tag":42,"props":605,"children":606},{},[607],{"type":34,"value":608},"sin predecir pancreatitis aguda",{"type":34,"value":207},{"type":21,"tag":91,"props":611,"children":613},{"href":252,"rel":612},[169],[614],{"type":34,"value":256},{"type":34,"value":616},"). Una revisión sistemática viva de 2026 que agrupa 31 ensayos controlados con placebo y más de 40.000 pacientes halló tasas de pancreatitis prácticamente idénticas con el fármaco frente al placebo (odds ratio ≈ 0.99) —aunque, siendo justos, esa revisión sigue siendo un ",{"type":21,"tag":91,"props":618,"children":621},{"href":619,"rel":620},"https:\u002F\u002Fwww.medrxiv.org\u002Fcontent\u002F10.64898\u002F2026.03.19.26348844v1",[169],[622],{"type":34,"value":623},"preprint",{"type":34,"value":625}," y aún no ha sido revisada por pares. Un análisis de 2024 constató incluso ",{"type":21,"tag":42,"props":627,"children":628},{},[629],{"type":34,"value":630},"menos",{"type":34,"value":632}," episodios de pancreatitis recurrente en pacientes de alto riesgo con fármacos GLP-1 (",{"type":21,"tag":91,"props":634,"children":637},{"href":635,"rel":636},"https:\u002F\u002Fwww.endocrine.org\u002Fnews-and-advocacy\u002Fnews-room\u002F2024\u002Fendo-2024-press-nassar",[169],[638],{"type":34,"value":639},"Nassar et al., ENDO 2024 — resumen de congreso",{"type":34,"value":641},"), probablemente porque los fármacos corrigen los desencadenantes de fondo. Y lo fundamental: la pancreatitis aguda es un diagnóstico clínico —los criterios de Atlanta revisados exigen dolor real ",{"type":21,"tag":30,"props":643,"children":644},{},[645],{"type":34,"value":646},"más",{"type":34,"value":648}," una lipasa por encima de tres veces el límite superior ",{"type":21,"tag":30,"props":650,"children":651},{},[652],{"type":34,"value":646},{"type":34,"value":654}," pruebas de imagen (",{"type":21,"tag":91,"props":656,"children":659},{"href":657,"rel":658},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F23100216\u002F",[169],[660],{"type":34,"value":661},"Banks et al., Gut 2013",{"type":34,"value":663},"). Un valor de laboratorio aislado no basta, y el salto de \"te ha subido la lipasa\" a \"tu páncreas se sobrecarga hasta fallar\" no se sostiene.",{"type":21,"tag":125,"props":665,"children":667},{"id":666},"afirmación-3-la-cascada-de-hígado-graso",[668],{"type":34,"value":669},"Afirmación 3: la \"cascada de hígado graso\"",{"type":21,"tag":26,"props":671,"children":672},{},[673],{"type":34,"value":674},"Esta es la inversión central, y la que más conviene entender bien.",{"type":21,"tag":26,"props":676,"children":677},{},[678],{"type":21,"tag":343,"props":679,"children":682},{"alt":680,"src":681},"La retatrutida reduce marcadamente la grasa hepática en los ensayos clínicos","\u002Fassets\u002Freta_liverfat.png",[],{"type":21,"tag":26,"props":684,"children":685},{},[686,688,693,695,700,702,707,709,714,716,721,723,728],{"type":34,"value":687},"Él plantea la retatrutida como algo que sobrecarga y daña el hígado —una \"cascada de hígado graso,\" una \"sobrecarga hepática.\" Los datos de los ensayos muestran ",{"type":21,"tag":42,"props":689,"children":690},{},[691],{"type":34,"value":692},"exactamente lo contrario.",{"type":34,"value":694}," En el estudio de fase 2 sobre grasa hepática, la retatrutida redujo la grasa del hígado de forma dependiente de la dosis: a las 48 semanas, ",{"type":21,"tag":42,"props":696,"children":697},{},[698],{"type":34,"value":699},"−81.7%",{"type":34,"value":701}," con 8 mg y ",{"type":21,"tag":42,"props":703,"children":704},{},[705],{"type":34,"value":706},"−86.0%",{"type":34,"value":708}," con 12 mg, frente a −4.6% con placebo. En el grupo de dosis máxima, ",{"type":21,"tag":42,"props":710,"children":711},{},[712],{"type":34,"value":713},"alrededor del 93% de los pacientes vieron caer su grasa hepática por debajo del umbral del 5%",{"type":34,"value":715}," —en la práctica, una normalización médica de su hígado graso (",{"type":21,"tag":91,"props":717,"children":719},{"href":284,"rel":718},[169],[720],{"type":34,"value":288},{"type":34,"value":722},"). Está entre las mayores reducciones de grasa hepática documentadas hasta ahora en el desarrollo clínico del fármaco. La retatrutida no es un peligro hepático oculto; se está desarrollando ",{"type":21,"tag":42,"props":724,"children":725},{},[726],{"type":34,"value":727},"como tratamiento para la enfermedad del hígado graso (MASLD)",{"type":34,"value":729},". Su efecto neto sobre el hígado, en ensayos controlados, es profundamente protector —lo contrario de la cascada que describe.",{"type":21,"tag":125,"props":731,"children":733},{"id":732},"en-qué-acierta",[734],{"type":34,"value":735},"En qué acierta",{"type":21,"tag":26,"props":737,"children":738},{},[739],{"type":34,"value":740},"Una verificación honesta reconoce los aciertos, no solo los fallos —y dos de sus argumentos de fondo son legítimos.",{"type":21,"tag":26,"props":742,"children":743},{},[744,746,750,752,757,759,764,765,772,774,781],{"type":34,"value":745},"Tiene razón en que ",{"type":21,"tag":42,"props":747,"children":748},{},[749],{"type":34,"value":198},{"type":34,"value":751}," conviene entrar en pánico y suspender el fármaco por una subida de lipasa aislada y sin síntomas; eso encaja de verdad con lo que dan a entender las guías de gastroenterología. Y tiene razón en que la pérdida rápida de peso con estos fármacos cuesta ",{"type":21,"tag":42,"props":753,"children":754},{},[755],{"type":34,"value":756},"masa magra",{"type":34,"value":758}," —desde alrededor de una cuarta parte hasta casi la mitad del peso perdido puede ser masa libre de grasa, en buena parte músculo (",{"type":21,"tag":91,"props":760,"children":762},{"href":310,"rel":761},[169],[763],{"type":34,"value":314},{"type":34,"value":216},{"type":21,"tag":91,"props":766,"children":769},{"href":767,"rel":768},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11450469\u002F",[169],[770],{"type":34,"value":771},"Tinsley et al., 2024",{"type":34,"value":773},"), y por eso la ingesta de proteína y el entrenamiento de fuerza deben formar parte de cualquier plan serio (",{"type":21,"tag":91,"props":775,"children":778},{"href":776,"rel":777},"https:\u002F\u002Fdiabetesjournals.org\u002Fcare\u002Farticle\u002F47\u002F10\u002F1718\u002F154535\u002F",[169],[779],{"type":34,"value":780},"Locatelli et al., Diabetes Care 2024",{"type":34,"value":782},"). Esos puntos son reales. El problema es el envoltorio que los rodea.",{"type":21,"tag":125,"props":784,"children":786},{"id":785},"el-patrón",[787],{"type":34,"value":788},"El patrón",{"type":21,"tag":26,"props":790,"children":791},{},[792],{"type":34,"value":793},"En nuestra valoración, la estructura aquí es de las de siempre: se usa terminología real para proyectar autoridad; se monta una \"cascada de daño\" aterradora que, según nuestra lectura de los datos del ensayo, la evidencia no respalda; se etiqueta a otras voces como \"desinformación\"; y el remedio propuesto es un protocolo de pago y péptidos de la propia tienda del autor. No pretendemos conocer su intención —describimos el efecto tal como lo vemos, y los lectores pueden sopesar por sí mismos el contexto comercial.",{"type":21,"tag":26,"props":795,"children":796},{},[797],{"type":34,"value":798},"La retatrutida es un fármaco experimental serio, con un perfil real de efectos secundarios (en su mayoría gastrointestinales, dependientes de la dosis y peores durante el escalado de dosis) y con verdaderos interrogantes abiertos sobre el uso a largo plazo y la pérdida de músculo. Merece cautela y un médico que la prescriba. No merece una narrativa fabricada de fallo orgánico de labios de alguien que vende el antídoto.",{"type":21,"tag":800,"props":801,"children":802},"hr",{},[],{"type":21,"tag":125,"props":804,"children":806},{"id":805},"el-panorama-científico-completo",[807],{"type":34,"value":808},"El panorama científico completo",{"type":21,"tag":26,"props":810,"children":811},{},[812],{"type":34,"value":813},"La sección de arriba es el veredicto. Esta parte son los deberes: una guía con referencias sobre lo que estos fármacos hacen de verdad, para que juzgues las afirmaciones por ti mismo en lugar de fiarte de la palabra de nadie —ni la nuestra ni la suya. Es densa a propósito.",{"type":21,"tag":125,"props":815,"children":817},{"id":816},"de-nafld-a-masld",[818],{"type":34,"value":819},"De NAFLD a MASLD",{"type":21,"tag":26,"props":821,"children":822},{},[823,825,830,832,839],{"type":34,"value":824},"Durante décadas, a la grasa que se acumula en el hígado sin un consumo elevado de alcohol se la llamó enfermedad del hígado graso no alcohólico (NAFLD) —hoy la afección hepática crónica más frecuente del planeta, que afecta a alrededor del 30–38% de los adultos. En 2023, un consenso internacional la rebautizó como ",{"type":21,"tag":42,"props":826,"children":827},{},[828],{"type":34,"value":829},"MASLD —enfermedad hepática esteatósica asociada a disfunción metabólica—",{"type":34,"value":831}," para poner en primer plano la causa metabólica de fondo, en vez de definir la enfermedad por lo que no es (",{"type":21,"tag":91,"props":833,"children":836},{"href":834,"rel":835},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10653297\u002F",[169],[837],{"type":34,"value":838},"Rinella et al., 2023",{"type":34,"value":233},{"type":21,"tag":26,"props":841,"children":842},{},[843,845,850,852,859,861,866],{"type":34,"value":844},"La progresión se describe con un ",{"type":21,"tag":42,"props":846,"children":847},{},[848],{"type":34,"value":849},"modelo de \"múltiples golpes\"",{"type":34,"value":851},": el primer golpe es la grasa que se acumula en las células hepáticas, lo que después vuelve al hígado vulnerable a nuevas agresiones —estrés oxidativo, disfunción mitocondrial, disbiosis intestino-hígado, inflamación (",{"type":21,"tag":91,"props":853,"children":856},{"href":854,"rel":855},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26823198\u002F",[169],[857],{"type":34,"value":858},"Buzzetti et al., 2016",{"type":34,"value":860},"). El espectro va desde la esteatosis simple, pasando por la esteatohepatitis (MASH) con inflamación y lesión celular, hasta la fibrosis, la cirrosis y el cáncer de hígado. El motor de esa progresión es la ",{"type":21,"tag":42,"props":862,"children":863},{},[864],{"type":34,"value":865},"lipotoxicidad",{"type":34,"value":867}," —no el triglicérido inerte en sí, sino intermediarios lipídicos tóxicos como las ceramidas y los diacilgliceroles que dañan la maquinaria celular y encienden vías inflamatorias.",{"type":21,"tag":125,"props":869,"children":871},{"id":870},"resistencia-hepática-selectiva-a-la-insulina",[872],{"type":34,"value":873},"Resistencia hepática selectiva a la insulina",{"type":21,"tag":26,"props":875,"children":876},{},[877,879,886,887,894],{"type":34,"value":878},"Una de las ideas más importantes aquí, desarrollada en gran medida por Samuel y Shulman, resuelve una paradoja: por qué un hígado diabético ignora la señal de la insulina para dejar de fabricar glucosa, pero aún obedece la señal de la insulina para fabricar grasa (",{"type":21,"tag":91,"props":880,"children":883},{"href":881,"rel":882},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC4701542\u002F",[169],[884],{"type":34,"value":885},"Samuel & Shulman, JCI 2016",{"type":34,"value":216},{"type":21,"tag":91,"props":888,"children":891},{"href":889,"rel":890},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC5762395\u002F",[169],[892],{"type":34,"value":893},"Cell Metabolism 2018",{"type":34,"value":233},{"type":21,"tag":26,"props":896,"children":897},{},[898,900,905,907,912,914,921,923,928],{"type":34,"value":899},"El mecanismo: a medida que la grasa se acumula en el hígado, se va acumulando ",{"type":21,"tag":42,"props":901,"children":902},{},[903],{"type":34,"value":904},"diacilglicerol",{"type":34,"value":906},", que activa una enzima (PKCε) que atasca la señal proximal de la insulina. La insulina ya no puede suprimir la producción de glucosa —así que el azúcar en sangre sube— pero la maquinaria de fabricar grasa sigue funcionando con sustrato en bruto y niveles altos de insulina. Súmale que el tejido graso resistente vierte ácidos grasos libres directamente al hígado, y obtienes un bucle de acumulación de grasa que se retroalimenta a sí mismo. Los estudios con isótopos ponen cifras a ese flujo de entrada: en pacientes con hígado graso, alrededor del ",{"type":21,"tag":42,"props":908,"children":909},{},[910],{"type":34,"value":911},"59% del triglicérido hepático almacenado procede de ácidos grasos libres circulantes",{"type":34,"value":913}," (lipólisis periférica), ~26% de la lipogénesis de novo y ~15% de la dieta (",{"type":21,"tag":91,"props":915,"children":918},{"href":916,"rel":917},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC1087172\u002F",[169],[919],{"type":34,"value":920},"Donnelly et al., JCI 2005",{"type":34,"value":922},"). Esta es la biología real a la que el vídeo alude —y es exactamente por lo que un fármaco que ",{"type":21,"tag":30,"props":924,"children":925},{},[926],{"type":34,"value":927},"reduce",{"type":34,"value":929}," ese flujo de grasa ayuda en lugar de dañar.",{"type":21,"tag":125,"props":931,"children":933},{"id":932},"qué-hace-el-glucagón-de-verdad-y-el-mito-de-la-grasa-blanca",[934],{"type":34,"value":935},"Qué hace el glucagón de verdad —y el mito de la grasa blanca",{"type":21,"tag":26,"props":937,"children":938},{},[939,941,946,948,953,954,961,962,968],{"type":34,"value":940},"El glucagón, presentado durante mucho tiempo como el mero opuesto de la insulina, se entiende hoy como un amplio regulador del metabolismo energético y lipídico. Su principal diana es el hígado, donde desencadena la liberación de glucosa y, algo importante, ",{"type":21,"tag":42,"props":942,"children":943},{},[944],{"type":34,"value":945},"impulsa la oxidación de grasa y suprime la síntesis de grasa nueva",{"type":34,"value":947}," a través de una vía de cAMP\u002FPKA y un mecanismo de liberación de calcio que activa la descomposición de grasa hepática (",{"type":21,"tag":91,"props":949,"children":951},{"href":210,"rel":950},[169],[952],{"type":34,"value":214},{"type":34,"value":216},{"type":21,"tag":91,"props":955,"children":958},{"href":956,"rel":957},"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fphysiology\u002Farticles\u002F10.3389\u002Ffphys.2019.00413\u002Ffull",[169],[959],{"type":34,"value":960},"Galsgaard et al., 2019",{"type":34,"value":216},{"type":21,"tag":91,"props":963,"children":965},{"href":553,"rel":964},[169],[966],{"type":34,"value":967},"Kajani et al., 2024",{"type":34,"value":969},"). Este \"quemado de grasa\" hepático es precisamente por lo que los desarrolladores de fármacos acoplaron una señal de glucagón a la retatrutida.",{"type":21,"tag":26,"props":971,"children":972},{},[973,975,980,982,987,989,994,995,1001,1003,1008],{"type":34,"value":974},"Pero —y aquí va la corrección del mito— esa acción es ",{"type":21,"tag":42,"props":976,"children":977},{},[978],{"type":34,"value":979},"hepática, no periférica.",{"type":34,"value":981}," Viejos experimentos in vitro mostraron que unas células grasas aisladas podían descomponer grasa cuando se las bañaba en glucagón, pero solo a concentraciones 10–100× superiores a las que el cuerpo llega a producir. El trabajo moderno lo zanja: quítale el receptor de glucagón al tejido graso y el metabolismo lipídico no cambia (",{"type":21,"tag":91,"props":983,"children":985},{"href":219,"rel":984},[169],[986],{"type":34,"value":223},{"type":34,"value":988},"); dale a un humano glucagón fisiológico y la lipólisis de la grasa abdominal no se inmuta (",{"type":21,"tag":91,"props":990,"children":992},{"href":227,"rel":991},[169],[993],{"type":34,"value":231},{"type":34,"value":216},{"type":21,"tag":91,"props":996,"children":998},{"href":527,"rel":997},[169],[999],{"type":34,"value":1000},"Jensen et al., 1991",{"type":34,"value":1002},"). La pérdida de peso con fármacos que contienen glucagón viene de la supresión del apetito, del aumento del gasto energético y de la oxidación de la grasa ",{"type":21,"tag":42,"props":1004,"children":1005},{},[1006],{"type":34,"value":1007},"hepática",{"type":34,"value":1009}," —no de que el glucagón disuelva tu grasa abdominal e inunde tus órganos.",{"type":21,"tag":125,"props":1011,"children":1013},{"id":1012},"el-salto-a-los-poliagonistas-de-la-semaglutida-a-la-retatrutida",[1014],{"type":34,"value":1015},"El salto a los poliagonistas: de la semaglutida a la retatrutida",{"type":21,"tag":26,"props":1017,"children":1018},{},[1019,1021,1026,1028,1035,1037,1042,1043,1050,1052,1059,1061,1068],{"type":34,"value":1020},"Los fármacos incretínicos son imitadores de hormonas intestinales, diseñados para resistir la degradación rápida y así durar. La primera oleada fueron los monoagonistas de GLP-1: la semaglutida produjo alrededor de un ",{"type":21,"tag":42,"props":1022,"children":1023},{},[1024],{"type":34,"value":1025},"14.9%",{"type":34,"value":1027}," de pérdida media de peso en su ensayo pivotal de obesidad (",{"type":21,"tag":91,"props":1029,"children":1032},{"href":1030,"rel":1031},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33567185\u002F",[169],[1033],{"type":34,"value":1034},"STEP 1, Wilding et al., NEJM 2021",{"type":34,"value":1036},"). Después llegó el agonismo dual GLP-1\u002FGIP: la tirzepatida alcanzó hasta un ",{"type":21,"tag":42,"props":1038,"children":1039},{},[1040],{"type":34,"value":1041},"20.9%",{"type":34,"value":207},{"type":21,"tag":91,"props":1044,"children":1047},{"href":1045,"rel":1046},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F35658024\u002F",[169],[1048],{"type":34,"value":1049},"SURMOUNT-1, Jastreboff et al., NEJM 2022",{"type":34,"value":1051},"). Para la fisiología de cómo colaboran estas hormonas, consulta ",{"type":21,"tag":91,"props":1053,"children":1056},{"href":1054,"rel":1055},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F39160334\u002F",[169],[1057],{"type":34,"value":1058},"Holst, Nature Metabolism 2024",{"type":34,"value":1060}," y ",{"type":21,"tag":91,"props":1062,"children":1065},{"href":1063,"rel":1064},"https:\u002F\u002Fdom-pubs.onlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Fdom.14496",[169],[1066],{"type":34,"value":1067},"Nauck et al., 2021",{"type":34,"value":183},{"type":21,"tag":26,"props":1070,"children":1071},{},[1072,1074,1079,1080,1087],{"type":34,"value":1073},"La retatrutida (LY3437943) va un paso más allá: una sola molécula que actúa sobre los receptores de ",{"type":21,"tag":42,"props":1075,"children":1076},{},[1077],{"type":34,"value":1078},"GLP-1, GIP y glucagón",{"type":34,"value":207},{"type":21,"tag":91,"props":1081,"children":1084},{"href":1082,"rel":1083},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04881760",[169],[1085],{"type":34,"value":1086},"ensayo NCT04881760",{"type":34,"value":1088},"). El brazo del glucagón añade oxidación de grasa hepática y gasto energético; los brazos de GLP-1 y GIP aportan supresión del apetito, apoyo de la insulina y —algo crucial— cancelan la tendencia del glucagón a subir el azúcar en sangre.",{"type":21,"tag":26,"props":1090,"children":1091},{},[1092,1094,1099,1101,1108,1110,1116,1118,1123],{"type":34,"value":1093},"Una nota sobre la nomenclatura: los datos de ",{"type":21,"tag":42,"props":1095,"children":1096},{},[1097],{"type":34,"value":1098},"fase 2",{"type":34,"value":1100}," de abajo proceden de ",{"type":21,"tag":91,"props":1102,"children":1105},{"href":1103,"rel":1104},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37366315\u002F",[169],[1106],{"type":34,"value":1107},"Jastreboff et al., NEJM 2023",{"type":34,"value":1109}," y del ",{"type":21,"tag":91,"props":1111,"children":1113},{"href":284,"rel":1112},[169],[1114],{"type":34,"value":1115},"subestudio MASLD, Sanyal et al., Nature Medicine 2024",{"type":34,"value":1117},". \"TRIUMPH\" es el posterior programa de ",{"type":21,"tag":30,"props":1119,"children":1120},{},[1121],{"type":34,"value":1122},"fase 3",{"type":34,"value":1124}," —así que no dejes que nadie te presente las cifras de fase 2 como resultados de TRIUMPH-1.",{"type":21,"tag":26,"props":1126,"children":1127},{},[1128,1133,1135,1141],{"type":21,"tag":42,"props":1129,"children":1130},{},[1131],{"type":34,"value":1132},"Cambio de peso a las 48 semanas",{"type":34,"value":1134}," (fase 2, n=338; ",{"type":21,"tag":91,"props":1136,"children":1138},{"href":1103,"rel":1137},[169],[1139],{"type":34,"value":1140},"Jastreboff et al., 2023",{"type":34,"value":1142},"):",{"type":21,"tag":1144,"props":1145,"children":1146},"table",{},[1147,1166],{"type":21,"tag":1148,"props":1149,"children":1150},"thead",{},[1151],{"type":21,"tag":1152,"props":1153,"children":1154},"tr",{},[1155,1161],{"type":21,"tag":1156,"props":1157,"children":1158},"th",{},[1159],{"type":34,"value":1160},"Dosis semanal",{"type":21,"tag":1156,"props":1162,"children":1163},{},[1164],{"type":34,"value":1165},"Cambio medio de peso",{"type":21,"tag":1167,"props":1168,"children":1169},"tbody",{},[1170,1184,1197,1210,1223],{"type":21,"tag":1152,"props":1171,"children":1172},{},[1173,1179],{"type":21,"tag":1174,"props":1175,"children":1176},"td",{},[1177],{"type":34,"value":1178},"Placebo",{"type":21,"tag":1174,"props":1180,"children":1181},{},[1182],{"type":34,"value":1183},"−2.1%",{"type":21,"tag":1152,"props":1185,"children":1186},{},[1187,1192],{"type":21,"tag":1174,"props":1188,"children":1189},{},[1190],{"type":34,"value":1191},"Retatrutide 1 mg",{"type":21,"tag":1174,"props":1193,"children":1194},{},[1195],{"type":34,"value":1196},"−8.7%",{"type":21,"tag":1152,"props":1198,"children":1199},{},[1200,1205],{"type":21,"tag":1174,"props":1201,"children":1202},{},[1203],{"type":34,"value":1204},"Retatrutide 4 mg",{"type":21,"tag":1174,"props":1206,"children":1207},{},[1208],{"type":34,"value":1209},"−17.1%",{"type":21,"tag":1152,"props":1211,"children":1212},{},[1213,1218],{"type":21,"tag":1174,"props":1214,"children":1215},{},[1216],{"type":34,"value":1217},"Retatrutide 8 mg",{"type":21,"tag":1174,"props":1219,"children":1220},{},[1221],{"type":34,"value":1222},"−22.8%",{"type":21,"tag":1152,"props":1224,"children":1225},{},[1226,1231],{"type":21,"tag":1174,"props":1227,"children":1228},{},[1229],{"type":34,"value":1230},"Retatrutide 12 mg",{"type":21,"tag":1174,"props":1232,"children":1233},{},[1234],{"type":34,"value":1235},"−24.2%",{"type":21,"tag":26,"props":1237,"children":1238},{},[1239,1244,1246,1252],{"type":21,"tag":42,"props":1240,"children":1241},{},[1242],{"type":34,"value":1243},"Cambio de grasa hepática a las 48 semanas",{"type":34,"value":1245}," (subestudio MASLD, n=98; ",{"type":21,"tag":91,"props":1247,"children":1249},{"href":284,"rel":1248},[169],[1250],{"type":34,"value":1251},"Sanyal et al., 2024",{"type":34,"value":1142},{"type":21,"tag":1144,"props":1254,"children":1255},{},[1256,1276],{"type":21,"tag":1148,"props":1257,"children":1258},{},[1259],{"type":21,"tag":1152,"props":1260,"children":1261},{},[1262,1266,1271],{"type":21,"tag":1156,"props":1263,"children":1264},{},[1265],{"type":34,"value":1160},{"type":21,"tag":1156,"props":1267,"children":1268},{},[1269],{"type":34,"value":1270},"Cambio relativo de grasa hepática",{"type":21,"tag":1156,"props":1272,"children":1273},{},[1274],{"type":34,"value":1275},"Grasa hepática normalizada (\u003C5%)",{"type":21,"tag":1167,"props":1277,"children":1278},{},[1279,1296,1313,1329],{"type":21,"tag":1152,"props":1280,"children":1281},{},[1282,1286,1291],{"type":21,"tag":1174,"props":1283,"children":1284},{},[1285],{"type":34,"value":1178},{"type":21,"tag":1174,"props":1287,"children":1288},{},[1289],{"type":34,"value":1290},"−4.6%",{"type":21,"tag":1174,"props":1292,"children":1293},{},[1294],{"type":34,"value":1295},"0%",{"type":21,"tag":1152,"props":1297,"children":1298},{},[1299,1303,1308],{"type":21,"tag":1174,"props":1300,"children":1301},{},[1302],{"type":34,"value":1191},{"type":21,"tag":1174,"props":1304,"children":1305},{},[1306],{"type":34,"value":1307},"−51.3%",{"type":21,"tag":1174,"props":1309,"children":1310},{},[1311],{"type":34,"value":1312},">50%",{"type":21,"tag":1152,"props":1314,"children":1315},{},[1316,1320,1324],{"type":21,"tag":1174,"props":1317,"children":1318},{},[1319],{"type":34,"value":1217},{"type":21,"tag":1174,"props":1321,"children":1322},{},[1323],{"type":34,"value":699},{"type":21,"tag":1174,"props":1325,"children":1326},{},[1327],{"type":34,"value":1328},"—",{"type":21,"tag":1152,"props":1330,"children":1331},{},[1332,1336,1340],{"type":21,"tag":1174,"props":1333,"children":1334},{},[1335],{"type":34,"value":1230},{"type":21,"tag":1174,"props":1337,"children":1338},{},[1339],{"type":34,"value":706},{"type":21,"tag":1174,"props":1341,"children":1342},{},[1343],{"type":34,"value":1344},"~93%",{"type":21,"tag":26,"props":1346,"children":1347},{},[1348],{"type":34,"value":1349},"Casi una cuarta parte del peso corporal esfumada en menos de un año, en magnitudes que antes solo alcanzaba la cirugía bariátrica —y un hígado graso normalizado en más de nueve de cada diez pacientes con la dosis máxima. Estos son los datos que una narrativa de \"sobrecarga hepática\" tiene que ignorar.",{"type":21,"tag":125,"props":1351,"children":1353},{"id":1352},"efectos-gastrointestinales-y-la-cuestión-de-la-anestesia",[1354],{"type":34,"value":1355},"Efectos gastrointestinales y la cuestión de la anestesia",{"type":21,"tag":26,"props":1357,"children":1358},{},[1359,1361,1366,1368,1373],{"type":34,"value":1360},"El precio de esta eficacia es sobre todo gastrointestinal. El vaciado gástrico ralentizado y la señalización de náuseas en el tronco encefálico hacen que ",{"type":21,"tag":42,"props":1362,"children":1363},{},[1364],{"type":34,"value":1365},"las náuseas, los vómitos, la diarrea y el estreñimiento",{"type":34,"value":1367}," sean los efectos secundarios habituales —dependientes de la dosis, peores durante el escalado de dosis y normalmente transitorios (",{"type":21,"tag":91,"props":1369,"children":1371},{"href":1103,"rel":1370},[169],[1372],{"type":34,"value":1140},{"type":34,"value":1374},"). La titulación lenta (empezar con dosis bajas) es la medida estándar para mitigarlos.",{"type":21,"tag":26,"props":1376,"children":1377},{},[1378,1380,1387,1388,1395,1397,1404,1406,1413,1415,1419],{"type":34,"value":1379},"Una consecuencia en la práctica clínica ha desatado un debate médico genuino: como estos fármacos ralentizan el vaciado gástrico, la comida puede quedarse más tiempo en el estómago, lo que aumenta la probabilidad de que queden restos gástricos antes de la anestesia, con el consiguiente riesgo teórico de aspiración. Los metaanálisis sí encuentran un contenido gástrico residual bastante mayor en los usuarios (",{"type":21,"tag":91,"props":1381,"children":1384},{"href":1382,"rel":1383},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11264430\u002F",[169],[1385],{"type":34,"value":1386},"do Nascimento et al., 2024",{"type":34,"value":216},{"type":21,"tag":91,"props":1389,"children":1392},{"href":1390,"rel":1391},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40133086\u002F",[169],[1393],{"type":34,"value":1394},"Tan et al., 2025",{"type":34,"value":1396},"), aunque los episodios reales de aspiración siguen siendo raros (",{"type":21,"tag":91,"props":1398,"children":1401},{"href":1399,"rel":1400},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11651700\u002F",[169],[1402],{"type":34,"value":1403},"Jalleh et al., JCEM 2024",{"type":34,"value":1405},"). Las sociedades de anestesia recomiendan ahora pausar el fármaco antes de procedimientos electivos (",{"type":21,"tag":91,"props":1407,"children":1410},{"href":1408,"rel":1409},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37982170\u002F",[169],[1411],{"type":34,"value":1412},"guía ASA, 2024",{"type":34,"value":1414},"). Es una precaución legítima y bien caracterizada —y, cosa notable, ",{"type":21,"tag":30,"props":1416,"children":1417},{},[1418],{"type":34,"value":198},{"type":34,"value":1420}," es en la que se centra el vídeo.",{"type":21,"tag":125,"props":1422,"children":1424},{"id":1423},"el-páncreas-cómo-funciona-y-la-cuestión-de-la-lipasa",[1425],{"type":34,"value":1426},"El páncreas: cómo funciona y la cuestión de la lipasa",{"type":21,"tag":26,"props":1428,"children":1429},{},[1430,1432,1438],{"type":34,"value":1431},"Más del 90% del páncreas es tejido exocrino —células acinares que fabrican enzimas digestivas. Almacenan precursores enzimáticos inactivos y los liberan cuando toca; la activación prematura dentro de la célula es lo que define la verdadera pancreatitis. Los receptores de GLP-1 están presentes en estas células acinares, de modo que los fármacos inducen la liberación de enzima como un efecto normal mediado por receptor (",{"type":21,"tag":91,"props":1433,"children":1435},{"href":593,"rel":1434},[169],[1436],{"type":34,"value":1437},"Hou… Williams et al., 2016",{"type":34,"value":233},{"type":21,"tag":26,"props":1440,"children":1441},{},[1442,1444,1449,1451,1457,1459,1464],{"type":34,"value":1443},"Por eso las elevaciones leves de lipasa y amilasa son tan comunes con la terapia —y por eso casi nunca significan nada. Son una ",{"type":21,"tag":30,"props":1445,"children":1446},{},[1447],{"type":34,"value":1448},"fuga",{"type":34,"value":1450}," de enzima estimulada, no destrucción de tejido. La evidencia de los ensayos (arriba) muestra que estas subidas no predicen pancreatitis (",{"type":21,"tag":91,"props":1452,"children":1454},{"href":252,"rel":1453},[169],[1455],{"type":34,"value":1456},"Steinberg et al., 2017",{"type":34,"value":1458},"), y los datos agrupados no muestran un exceso de riesgo de pancreatitis frente al placebo. El riesgo de fondo que sí existe tiene que ver con la propia población —las personas con obesidad y diabetes tipo 2 arrastran un riesgo basal de pancreatitis mayor por cálculos biliares y triglicéridos altos, con independencia de cualquier fármaco. Tratar esos factores de fondo es, probablemente, la razón por la que algunos datos muestran una ",{"type":21,"tag":42,"props":1460,"children":1461},{},[1462],{"type":34,"value":1463},"reducción",{"type":34,"value":1465}," de la recurrencia con la terapia GLP-1.",{"type":21,"tag":125,"props":1467,"children":1469},{"id":1468},"la-verdadera-salvedad-perder-masa-magra",[1470],{"type":34,"value":1471},"La verdadera salvedad: perder masa magra",{"type":21,"tag":26,"props":1473,"children":1474},{},[1475,1477,1482,1484,1489,1490,1495,1497,1503],{"type":34,"value":1476},"Si hay una advertencia que merece los minutos que el vídeo dedica al daño orgánico fantasma, es esta. A lo largo de los ensayos con incretinas, una parte sustancial del peso perdido es ",{"type":21,"tag":42,"props":1478,"children":1479},{},[1480],{"type":34,"value":1481},"masa libre de grasa",{"type":34,"value":1483}," —en torno a un 25–40%, en buena parte músculo esquelético (",{"type":21,"tag":91,"props":1485,"children":1487},{"href":310,"rel":1486},[169],[1488],{"type":34,"value":314},{"type":34,"value":216},{"type":21,"tag":91,"props":1491,"children":1493},{"href":767,"rel":1492},[169],[1494],{"type":34,"value":771},{"type":34,"value":1496},"). Esto no es exclusivo de estos fármacos —cualquier pérdida de peso grande y rápida lo provoca— pero perder músculo baja la tasa metabólica (lo que alimenta el rebote tras dejarlos), reduce la sensibilidad a la insulina y aumenta la fragilidad y el riesgo de caídas en las personas mayores. La solución avalada por la evidencia es poco glamurosa: proteína suficiente y entrenamiento de fuerza progresivo junto con la medicación (",{"type":21,"tag":91,"props":1498,"children":1500},{"href":776,"rel":1499},[169],[1501],{"type":34,"value":1502},"Locatelli et al., 2024",{"type":34,"value":233},{"type":21,"tag":125,"props":1505,"children":1507},{"id":1506},"nuevas-fronteras-inmunometabolismo-y-cáncer",[1508],{"type":34,"value":1509},"Nuevas fronteras: inmunometabolismo y cáncer",{"type":21,"tag":26,"props":1511,"children":1512},{},[1513,1515,1522],{"type":34,"value":1514},"Por último, un vistazo a dónde se dirige la ciencia. La obesidad impulsa la inflamación crónica y \"agota\" metabólicamente a las células inmunitarias que combaten los tumores. Los primeros trabajos sugieren que los fármacos GLP-1 pueden revertir esto en parte: en modelos de ratón obeso de cáncer de pulmón, un agonista de GLP-1 ralentizó el crecimiento del tumor y mejoró el entorno inmunitario antitumoral —un efecto observado solo en animales obesos (",{"type":21,"tag":91,"props":1516,"children":1519},{"href":1517,"rel":1518},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40857107\u002F",[169],[1520],{"type":34,"value":1521},"Pachimatla… Sanghvi et al., JCI Insight 2025",{"type":34,"value":1523},"). Es preclínico y temprano, pero insinúa que corregir la disfunción metabólica puede tener beneficios mucho más allá de la báscula.",{"type":21,"tag":125,"props":1525,"children":1527},{"id":1526},"el-veredicto-honesto",[1528],{"type":34,"value":1529},"El veredicto honesto",{"type":21,"tag":26,"props":1531,"children":1532},{},[1533,1535,1539,1541,1545,1547,1551],{"type":34,"value":1534},"Junta toda la evidencia y el cuadro es el inverso del que pinta el vídeo. En ensayos controlados, la retatrutida ",{"type":21,"tag":42,"props":1536,"children":1537},{},[1538],{"type":34,"value":927},{"type":34,"value":1540}," la grasa hepática de forma drástica, ",{"type":21,"tag":42,"props":1542,"children":1543},{},[1544],{"type":34,"value":198},{"type":34,"value":1546}," aumenta el riesgo de pancreatitis y ",{"type":21,"tag":42,"props":1548,"children":1549},{},[1550],{"type":34,"value":198},{"type":34,"value":1552}," disuelve tu grasa corporal mediante ninguna inundación de glucagón. Las verdaderas precauciones —la pérdida de músculo, los efectos gastrointestinales, la interacción con la anestesia y el hecho rotundo de que el producto del mercado gris no está regulado y puede no ser lo que dice la etiqueta— son justo aquellas en las que quien te vende péptidos tiene el menor incentivo para detenerse.",{"type":21,"tag":26,"props":1554,"children":1555},{},[1556,1558,1562,1564,1570,1572,1578],{"type":34,"value":1557},"Si estás considerando o ya usando algo de esto, lo que toca no es un vídeo de 45 minutos y un botón de compra. Es un análisis de sangre, un prescriptor de verdad y expectativas honestas. Si algo no te cuadra, ",{"type":21,"tag":42,"props":1559,"children":1560},{},[1561],{"type":34,"value":113},{"type":34,"value":1563}," antes de confiar en un protocolo que vende la misma persona que te diagnosticó en YouTube. Para las dosis de los ensayos tal como se recogen en la literatura publicada, consulta nuestra ",{"type":21,"tag":91,"props":1565,"children":1567},{"href":1566},"\u002Fglp1\u002Fretatrutide",[1568],{"type":34,"value":1569},"referencia de la retatrutida",{"type":34,"value":1571},"; para entender primero la clase de fármacos, empieza por ",{"type":21,"tag":91,"props":1573,"children":1575},{"href":1574},"\u002Fwhat-are-peptides",[1576],{"type":34,"value":1577},"qué son los péptidos",{"type":34,"value":183},{"type":21,"tag":125,"props":1580,"children":1582},{"id":1581},"referencias",[1583],{"type":34,"value":1584},"Referencias",{"type":21,"tag":1586,"props":1587,"children":1588},"ol",{},[1589,1623,1655,1672,1694,1716,1740,1764,1787,1809,1832,1855,1880,1909,1932,1954,1976,1998,2020,2042,2064,2087,2109,2131,2153,2175,2196,2218,2240,2261,2283,2305,2323,2339,2356,2373],{"type":21,"tag":148,"props":1590,"children":1591},{},[1592,1594,1599,1601,1606,1608,1614,1616],{"type":34,"value":1593},"Jastreboff AM, Kaplan LM, Frías JP, et al. ",{"type":21,"tag":42,"props":1595,"children":1596},{},[1597],{"type":34,"value":1598},"Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.",{"type":34,"value":1600}," ",{"type":21,"tag":30,"props":1602,"children":1603},{},[1604],{"type":34,"value":1605},"N Engl J Med",{"type":34,"value":1607}," 2023. ",{"type":21,"tag":91,"props":1609,"children":1611},{"href":1103,"rel":1610},[169],[1612],{"type":34,"value":1613},"PubMed",{"type":34,"value":1615}," · ",{"type":21,"tag":91,"props":1617,"children":1620},{"href":1618,"rel":1619},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2301972",[169],[1621],{"type":34,"value":1622},"NEJM",{"type":21,"tag":148,"props":1624,"children":1625},{},[1626,1628,1633,1634,1639,1641,1647,1648],{"type":34,"value":1627},"Sanyal AJ, et al. ",{"type":21,"tag":42,"props":1629,"children":1630},{},[1631],{"type":34,"value":1632},"Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial.",{"type":34,"value":1600},{"type":21,"tag":30,"props":1635,"children":1636},{},[1637],{"type":34,"value":1638},"Nature Medicine",{"type":34,"value":1640}," 2024. ",{"type":21,"tag":91,"props":1642,"children":1644},{"href":284,"rel":1643},[169],[1645],{"type":34,"value":1646},"Texto completo en PMC",{"type":34,"value":1615},{"type":21,"tag":91,"props":1649,"children":1652},{"href":1650,"rel":1651},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41591-024-03018-2",[169],[1653],{"type":34,"value":1654},"Nature",{"type":21,"tag":148,"props":1656,"children":1657},{},[1658,1660,1665,1666],{"type":34,"value":1659},"Registro del ensayo de fase 2 de retatrutida en obesidad. ",{"type":21,"tag":30,"props":1661,"children":1662},{},[1663],{"type":34,"value":1664},"ClinicalTrials.gov",{"type":34,"value":1600},{"type":21,"tag":91,"props":1667,"children":1669},{"href":1082,"rel":1668},[169],[1670],{"type":34,"value":1671},"NCT04881760",{"type":21,"tag":148,"props":1673,"children":1674},{},[1675,1677,1682,1683,1687,1689],{"type":34,"value":1676},"Perry RJ, et al. ",{"type":21,"tag":42,"props":1678,"children":1679},{},[1680],{"type":34,"value":1681},"Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis.",{"type":34,"value":1600},{"type":21,"tag":30,"props":1684,"children":1685},{},[1686],{"type":34,"value":1654},{"type":34,"value":1688}," 2020. ",{"type":21,"tag":91,"props":1690,"children":1692},{"href":210,"rel":1691},[169],[1693],{"type":34,"value":1613},{"type":21,"tag":148,"props":1695,"children":1696},{},[1697,1699,1704,1705,1710,1711],{"type":34,"value":1698},"Kajani S, et al. ",{"type":21,"tag":42,"props":1700,"children":1701},{},[1702],{"type":34,"value":1703},"Hepatic glucagon action: beyond glucose mobilization.",{"type":34,"value":1600},{"type":21,"tag":30,"props":1706,"children":1707},{},[1708],{"type":34,"value":1709},"Physiological Reviews",{"type":34,"value":1640},{"type":21,"tag":91,"props":1712,"children":1714},{"href":553,"rel":1713},[169],[1715],{"type":34,"value":1613},{"type":21,"tag":148,"props":1717,"children":1718},{},[1719,1721,1726,1727,1732,1734],{"type":34,"value":1720},"Galsgaard KD, et al. ",{"type":21,"tag":42,"props":1722,"children":1723},{},[1724],{"type":34,"value":1725},"Glucagon Receptor Signaling and Lipid Metabolism.",{"type":34,"value":1600},{"type":21,"tag":30,"props":1728,"children":1729},{},[1730],{"type":34,"value":1731},"Front Physiol",{"type":34,"value":1733}," 2019. ",{"type":21,"tag":91,"props":1735,"children":1737},{"href":956,"rel":1736},[169],[1738],{"type":34,"value":1739},"Texto completo",{"type":21,"tag":148,"props":1741,"children":1742},{},[1743,1745,1750,1751,1756,1758],{"type":34,"value":1744},"Vasileva A, et al. ",{"type":21,"tag":42,"props":1746,"children":1747},{},[1748],{"type":34,"value":1749},"Glucagon receptor signaling at white adipose tissue does not regulate lipolysis.",{"type":34,"value":1600},{"type":21,"tag":30,"props":1752,"children":1753},{},[1754],{"type":34,"value":1755},"Am J Physiol Endocrinol Metab",{"type":34,"value":1757}," 2022. ",{"type":21,"tag":91,"props":1759,"children":1761},{"href":219,"rel":1760},[169],[1762],{"type":34,"value":1763},"PMC",{"type":21,"tag":148,"props":1765,"children":1766},{},[1767,1769,1774,1775,1780,1782],{"type":34,"value":1768},"Gravholt CH, et al. ",{"type":21,"tag":42,"props":1770,"children":1771},{},[1772],{"type":34,"value":1773},"Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue.",{"type":34,"value":1600},{"type":21,"tag":30,"props":1776,"children":1777},{},[1778],{"type":34,"value":1779},"JCEM",{"type":34,"value":1781}," 2001. ",{"type":21,"tag":91,"props":1783,"children":1785},{"href":227,"rel":1784},[169],[1786],{"type":34,"value":1613},{"type":21,"tag":148,"props":1788,"children":1789},{},[1790,1792,1797,1798,1802,1804],{"type":34,"value":1791},"Jensen MD, et al. ",{"type":21,"tag":42,"props":1793,"children":1794},{},[1795],{"type":34,"value":1796},"Effects of glucagon on free fatty acid metabolism in humans.",{"type":34,"value":1600},{"type":21,"tag":30,"props":1799,"children":1800},{},[1801],{"type":34,"value":1779},{"type":34,"value":1803}," 1991. ",{"type":21,"tag":91,"props":1805,"children":1807},{"href":527,"rel":1806},[169],[1808],{"type":34,"value":1613},{"type":21,"tag":148,"props":1810,"children":1811},{},[1812,1814,1819,1820,1825,1827],{"type":34,"value":1813},"Hou Y, Ernst SA, Heidenreich K, Williams JA. ",{"type":21,"tag":42,"props":1815,"children":1816},{},[1817],{"type":34,"value":1818},"GLP-1 receptor is present in pancreatic acinar cells and regulates amylase secretion.",{"type":34,"value":1600},{"type":21,"tag":30,"props":1821,"children":1822},{},[1823],{"type":34,"value":1824},"Am J Physiol Gastrointest Liver Physiol",{"type":34,"value":1826}," 2016. ",{"type":21,"tag":91,"props":1828,"children":1830},{"href":593,"rel":1829},[169],[1831],{"type":34,"value":1763},{"type":21,"tag":148,"props":1833,"children":1834},{},[1835,1837,1842,1843,1848,1850],{"type":34,"value":1836},"Steinberg WM, et al. ",{"type":21,"tag":42,"props":1838,"children":1839},{},[1840],{"type":34,"value":1841},"Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide (LEADER).",{"type":34,"value":1600},{"type":21,"tag":30,"props":1844,"children":1845},{},[1846],{"type":34,"value":1847},"Diabetes Care",{"type":34,"value":1849}," 2017. ",{"type":21,"tag":91,"props":1851,"children":1853},{"href":252,"rel":1852},[169],[1854],{"type":34,"value":1613},{"type":21,"tag":148,"props":1856,"children":1857},{},[1858,1860,1865,1867,1872,1874],{"type":34,"value":1859},"GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review. ",{"type":21,"tag":30,"props":1861,"children":1862},{},[1863],{"type":34,"value":1864},"medRxiv",{"type":34,"value":1866}," 2026 (",{"type":21,"tag":42,"props":1868,"children":1869},{},[1870],{"type":34,"value":1871},"preprint, aún sin revisión por pares",{"type":34,"value":1873},"). ",{"type":21,"tag":91,"props":1875,"children":1877},{"href":619,"rel":1876},[169],[1878],{"type":34,"value":1879},"Preprint",{"type":21,"tag":148,"props":1881,"children":1882},{},[1883,1885,1890,1891,1896,1897,1902,1903],{"type":34,"value":1884},"Nassar M, et al. ",{"type":21,"tag":42,"props":1886,"children":1887},{},[1888],{"type":34,"value":1889},"GLP-1 medications may lower risk of recurrent acute pancreatitis.",{"type":34,"value":1600},{"type":21,"tag":30,"props":1892,"children":1893},{},[1894],{"type":34,"value":1895},"ENDO 2024",{"type":34,"value":207},{"type":21,"tag":42,"props":1898,"children":1899},{},[1900],{"type":34,"value":1901},"resumen de congreso",{"type":34,"value":1873},{"type":21,"tag":91,"props":1904,"children":1906},{"href":635,"rel":1905},[169],[1907],{"type":34,"value":1908},"Nota de prensa",{"type":21,"tag":148,"props":1910,"children":1911},{},[1912,1914,1919,1920,1925,1927],{"type":34,"value":1913},"Banks PA, et al. ",{"type":21,"tag":42,"props":1915,"children":1916},{},[1917],{"type":34,"value":1918},"Classification of acute pancreatitis — 2012: revision of the Atlanta classification.",{"type":34,"value":1600},{"type":21,"tag":30,"props":1921,"children":1922},{},[1923],{"type":34,"value":1924},"Gut",{"type":34,"value":1926}," 2013. ",{"type":21,"tag":91,"props":1928,"children":1930},{"href":657,"rel":1929},[169],[1931],{"type":34,"value":1613},{"type":21,"tag":148,"props":1933,"children":1934},{},[1935,1937,1942,1943,1948,1949],{"type":34,"value":1936},"Rinella ME, et al. ",{"type":21,"tag":42,"props":1938,"children":1939},{},[1940],{"type":34,"value":1941},"A multisociety Delphi consensus on new fatty liver disease nomenclature (MASLD).",{"type":34,"value":1600},{"type":21,"tag":30,"props":1944,"children":1945},{},[1946],{"type":34,"value":1947},"Hepatology \u002F J Hepatol",{"type":34,"value":1607},{"type":21,"tag":91,"props":1950,"children":1952},{"href":834,"rel":1951},[169],[1953],{"type":34,"value":1763},{"type":21,"tag":148,"props":1955,"children":1956},{},[1957,1959,1964,1965,1970,1971],{"type":34,"value":1958},"Samuel VT, Shulman GI. ",{"type":21,"tag":42,"props":1960,"children":1961},{},[1962],{"type":34,"value":1963},"The pathogenesis of insulin resistance.",{"type":34,"value":1600},{"type":21,"tag":30,"props":1966,"children":1967},{},[1968],{"type":34,"value":1969},"J Clin Invest",{"type":34,"value":1826},{"type":21,"tag":91,"props":1972,"children":1974},{"href":881,"rel":1973},[169],[1975],{"type":34,"value":1763},{"type":21,"tag":148,"props":1977,"children":1978},{},[1979,1980,1985,1986,1991,1993],{"type":34,"value":1958},{"type":21,"tag":42,"props":1981,"children":1982},{},[1983],{"type":34,"value":1984},"NAFLD as a Nexus of Metabolic and Hepatic Diseases.",{"type":34,"value":1600},{"type":21,"tag":30,"props":1987,"children":1988},{},[1989],{"type":34,"value":1990},"Cell Metabolism",{"type":34,"value":1992}," 2018. ",{"type":21,"tag":91,"props":1994,"children":1996},{"href":889,"rel":1995},[169],[1997],{"type":34,"value":1763},{"type":21,"tag":148,"props":1999,"children":2000},{},[2001,2003,2008,2009,2014,2015],{"type":34,"value":2002},"Buzzetti E, Pinzani M, Tsochatzis EA. ",{"type":21,"tag":42,"props":2004,"children":2005},{},[2006],{"type":34,"value":2007},"The multiple-hit pathogenesis of NAFLD.",{"type":34,"value":1600},{"type":21,"tag":30,"props":2010,"children":2011},{},[2012],{"type":34,"value":2013},"Metabolism",{"type":34,"value":1826},{"type":21,"tag":91,"props":2016,"children":2018},{"href":854,"rel":2017},[169],[2019],{"type":34,"value":1613},{"type":21,"tag":148,"props":2021,"children":2022},{},[2023,2025,2030,2031,2035,2037],{"type":34,"value":2024},"Donnelly KL, et al. ",{"type":21,"tag":42,"props":2026,"children":2027},{},[2028],{"type":34,"value":2029},"Sources of fatty acids stored in liver and secreted via lipoproteins in NAFLD.",{"type":34,"value":1600},{"type":21,"tag":30,"props":2032,"children":2033},{},[2034],{"type":34,"value":1969},{"type":34,"value":2036}," 2005. ",{"type":21,"tag":91,"props":2038,"children":2040},{"href":916,"rel":2039},[169],[2041],{"type":34,"value":1763},{"type":21,"tag":148,"props":2043,"children":2044},{},[2045,2047,2052,2053,2057,2058],{"type":34,"value":2046},"Locatelli JC, et al. ",{"type":21,"tag":42,"props":2048,"children":2049},{},[2050],{"type":34,"value":2051},"Incretin-Based Weight Loss and Resistance Exercise.",{"type":34,"value":1600},{"type":21,"tag":30,"props":2054,"children":2055},{},[2056],{"type":34,"value":1847},{"type":34,"value":1640},{"type":21,"tag":91,"props":2059,"children":2061},{"href":776,"rel":2060},[169],[2062],{"type":34,"value":2063},"Artículo",{"type":21,"tag":148,"props":2065,"children":2066},{},[2067,2069,2074,2075,2080,2082],{"type":34,"value":2068},"Koceva A, et al. ",{"type":21,"tag":42,"props":2070,"children":2071},{},[2072],{"type":34,"value":2073},"Impact of Incretin-Based Therapy on Skeletal Muscle Health.",{"type":34,"value":1600},{"type":21,"tag":30,"props":2076,"children":2077},{},[2078],{"type":34,"value":2079},"Medicina",{"type":34,"value":2081}," 2025. ",{"type":21,"tag":91,"props":2083,"children":2085},{"href":310,"rel":2084},[169],[2086],{"type":34,"value":1763},{"type":21,"tag":148,"props":2088,"children":2089},{},[2090,2092,2097,2098,2103,2104],{"type":34,"value":2091},"Tinsley GM, et al. ",{"type":21,"tag":42,"props":2093,"children":2094},{},[2095],{"type":34,"value":2096},"Body Composition Principles for Fat-Free and Skeletal Muscle Mass Changes.",{"type":34,"value":1600},{"type":21,"tag":30,"props":2099,"children":2100},{},[2101],{"type":34,"value":2102},"J Endocr Soc",{"type":34,"value":1640},{"type":21,"tag":91,"props":2105,"children":2107},{"href":767,"rel":2106},[169],[2108],{"type":34,"value":1763},{"type":21,"tag":148,"props":2110,"children":2111},{},[2112,2114,2119,2120,2125,2126],{"type":34,"value":2113},"do Nascimento TS, et al. ",{"type":21,"tag":42,"props":2115,"children":2116},{},[2117],{"type":34,"value":2118},"GLP-1 receptor agonists and residual gastric content (perioperative).",{"type":34,"value":1600},{"type":21,"tag":30,"props":2121,"children":2122},{},[2123],{"type":34,"value":2124},"Perioper Med",{"type":34,"value":1640},{"type":21,"tag":91,"props":2127,"children":2129},{"href":1382,"rel":2128},[169],[2130],{"type":34,"value":1763},{"type":21,"tag":148,"props":2132,"children":2133},{},[2134,2136,2141,2142,2147,2148],{"type":34,"value":2135},"Tan Y, et al. ",{"type":21,"tag":42,"props":2137,"children":2138},{},[2139],{"type":34,"value":2140},"GLP-1 receptor agonists increase residual gastric content and aspiration risk.",{"type":34,"value":1600},{"type":21,"tag":30,"props":2143,"children":2144},{},[2145],{"type":34,"value":2146},"Dig Liver Dis",{"type":34,"value":2081},{"type":21,"tag":91,"props":2149,"children":2151},{"href":1390,"rel":2150},[169],[2152],{"type":34,"value":1613},{"type":21,"tag":148,"props":2154,"children":2155},{},[2156,2158,2163,2164,2169,2170],{"type":34,"value":2157},"Ushakumari DS, et al. ",{"type":21,"tag":42,"props":2159,"children":2160},{},[2161],{"type":34,"value":2162},"ASA Consensus-based Guidance on Preoperative Management of GLP-1 RAs.",{"type":34,"value":1600},{"type":21,"tag":30,"props":2165,"children":2166},{},[2167],{"type":34,"value":2168},"Anesthesiology",{"type":34,"value":1640},{"type":21,"tag":91,"props":2171,"children":2173},{"href":1408,"rel":2172},[169],[2174],{"type":34,"value":1613},{"type":21,"tag":148,"props":2176,"children":2177},{},[2178,2180,2185,2186,2190,2191],{"type":34,"value":2179},"Jalleh RJ, et al. ",{"type":21,"tag":42,"props":2181,"children":2182},{},[2183],{"type":34,"value":2184},"Clinical Consequences of Delayed Gastric Emptying With GLP-1 RAs.",{"type":34,"value":1600},{"type":21,"tag":30,"props":2187,"children":2188},{},[2189],{"type":34,"value":1779},{"type":34,"value":1640},{"type":21,"tag":91,"props":2192,"children":2194},{"href":1399,"rel":2193},[169],[2195],{"type":34,"value":1763},{"type":21,"tag":148,"props":2197,"children":2198},{},[2199,2201,2206,2207,2212,2213],{"type":34,"value":2200},"Pachimatla AG, … Sanghvi VR, et al. ",{"type":21,"tag":42,"props":2202,"children":2203},{},[2204],{"type":34,"value":2205},"GLP-1 receptor agonism improves lung cancer outcomes and tumor immunity (obese models).",{"type":34,"value":1600},{"type":21,"tag":30,"props":2208,"children":2209},{},[2210],{"type":34,"value":2211},"JCI Insight",{"type":34,"value":2081},{"type":21,"tag":91,"props":2214,"children":2216},{"href":1517,"rel":2215},[169],[2217],{"type":34,"value":1613},{"type":21,"tag":148,"props":2219,"children":2220},{},[2221,2223,2228,2229,2233,2235],{"type":34,"value":2222},"Wilding JPH, et al. ",{"type":21,"tag":42,"props":2224,"children":2225},{},[2226],{"type":34,"value":2227},"Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).",{"type":34,"value":1600},{"type":21,"tag":30,"props":2230,"children":2231},{},[2232],{"type":34,"value":1605},{"type":34,"value":2234}," 2021. ",{"type":21,"tag":91,"props":2236,"children":2238},{"href":1030,"rel":2237},[169],[2239],{"type":34,"value":1613},{"type":21,"tag":148,"props":2241,"children":2242},{},[2243,2245,2250,2251,2255,2256],{"type":34,"value":2244},"Jastreboff AM, et al. ",{"type":21,"tag":42,"props":2246,"children":2247},{},[2248],{"type":34,"value":2249},"Tirzepatide Once Weekly for Obesity (SURMOUNT-1).",{"type":34,"value":1600},{"type":21,"tag":30,"props":2252,"children":2253},{},[2254],{"type":34,"value":1605},{"type":34,"value":1757},{"type":21,"tag":91,"props":2257,"children":2259},{"href":1045,"rel":2258},[169],[2260],{"type":34,"value":1613},{"type":21,"tag":148,"props":2262,"children":2263},{},[2264,2266,2271,2272,2277,2278],{"type":34,"value":2265},"Holst JJ. ",{"type":21,"tag":42,"props":2267,"children":2268},{},[2269],{"type":34,"value":2270},"GLP-1 physiology in obesity and incretin-based drugs.",{"type":34,"value":1600},{"type":21,"tag":30,"props":2273,"children":2274},{},[2275],{"type":34,"value":2276},"Nature Metabolism",{"type":34,"value":1640},{"type":21,"tag":91,"props":2279,"children":2281},{"href":1054,"rel":2280},[169],[2282],{"type":34,"value":1613},{"type":21,"tag":148,"props":2284,"children":2285},{},[2286,2288,2293,2294,2299,2300],{"type":34,"value":2287},"Nauck MA, et al. ",{"type":21,"tag":42,"props":2289,"children":2290},{},[2291],{"type":34,"value":2292},"The evolving story of incretins (GIP and GLP-1).",{"type":34,"value":1600},{"type":21,"tag":30,"props":2295,"children":2296},{},[2297],{"type":34,"value":2298},"Diabetes Obes Metab",{"type":34,"value":2234},{"type":21,"tag":91,"props":2301,"children":2303},{"href":1063,"rel":2302},[169],[2304],{"type":34,"value":2063},{"type":21,"tag":148,"props":2306,"children":2307},{},[2308,2310,2315,2317],{"type":34,"value":2309},"Junta de Examinadores de Quiropráctica de California. ",{"type":21,"tag":42,"props":2311,"children":2312},{},[2313],{"type":34,"value":2314},"Materiales de la reunión, 29 oct 2020",{"type":34,"value":2316}," (licencia DC 29377, revocada el 8 jul 2020). ",{"type":21,"tag":91,"props":2318,"children":2320},{"href":167,"rel":2319},[169],[2321],{"type":34,"value":2322},"PDF",{"type":21,"tag":148,"props":2324,"children":2325},{},[2326,2327,2332,2333],{"type":34,"value":2309},{"type":21,"tag":42,"props":2328,"children":2329},{},[2330],{"type":34,"value":2331},"Acciones disciplinarias definitivas.",{"type":34,"value":1600},{"type":21,"tag":91,"props":2334,"children":2336},{"href":382,"rel":2335},[169],[2337],{"type":34,"value":2338},"Página",{"type":21,"tag":148,"props":2340,"children":2341},{},[2342,2344,2349,2350],{"type":34,"value":2343},"Departamento de Asuntos del Consumidor de California. ",{"type":21,"tag":42,"props":2345,"children":2346},{},[2347],{"type":34,"value":2348},"Buscador de licencias.",{"type":34,"value":1600},{"type":21,"tag":91,"props":2351,"children":2353},{"href":391,"rel":2352},[169],[2354],{"type":34,"value":2355},"Buscador",{"type":21,"tag":148,"props":2357,"children":2358},{},[2359,2361,2366,2367],{"type":34,"value":2360},"EliteBiogenix. ",{"type":21,"tag":42,"props":2362,"children":2363},{},[2364],{"type":34,"value":2365},"Vendedor de péptidos de investigación y SARM (solo investigación in vitro).",{"type":34,"value":1600},{"type":21,"tag":91,"props":2368,"children":2370},{"href":177,"rel":2369},[169],[2371],{"type":34,"value":2372},"Sitio web",{"type":21,"tag":148,"props":2374,"children":2375},{},[2376,2378,2383,2384,2389,2390],{"type":34,"value":2377},"Bachmeyer T. ",{"type":21,"tag":42,"props":2379,"children":2380},{},[2381],{"type":34,"value":2382},"\"Mega Dosing vs Micro Dosing Retatrutide: Which Damages Your Liver More?\"",{"type":34,"value":1600},{"type":21,"tag":30,"props":2385,"children":2386},{},[2387],{"type":34,"value":2388},"YouTube.",{"type":34,"value":1600},{"type":21,"tag":91,"props":2391,"children":2394},{"href":2392,"rel":2393},"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=gb-XEtsMr-w",[169],[2395],{"type":34,"value":2396},"Vídeo",{"title":7,"searchDepth":2398,"depth":2398,"links":2399},2,[2400,2401,2402,2403,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414,2415,2416,2417,2418],{"id":127,"depth":2398,"text":130},{"id":330,"depth":2398,"text":333},{"id":419,"depth":2398,"text":422},{"id":481,"depth":2398,"text":484},{"id":562,"depth":2398,"text":565},{"id":666,"depth":2398,"text":669},{"id":732,"depth":2398,"text":735},{"id":785,"depth":2398,"text":788},{"id":805,"depth":2398,"text":808},{"id":816,"depth":2398,"text":819},{"id":870,"depth":2398,"text":873},{"id":932,"depth":2398,"text":935},{"id":1012,"depth":2398,"text":1015},{"id":1352,"depth":2398,"text":1355},{"id":1423,"depth":2398,"text":1426},{"id":1468,"depth":2398,"text":1471},{"id":1506,"depth":2398,"text":1509},{"id":1526,"depth":2398,"text":1529},{"id":1581,"depth":2398,"text":1584},"markdown","content:blog:es:retatrutide-liver-damage-myths.md","content","blog\u002Fes\u002Fretatrutide-liver-damage-myths.md","blog\u002Fes\u002Fretatrutide-liver-damage-myths","md"]